Animal Disinfectants Market Growth Drivers, Trends, Top Companies, Key Segments, and Forecast (2024-2029)
Animal Disinfectants Market by Type (Iodine, Lactic Acid, Hydrogen Peroxide), Application (Dairy Cleaning, Swine, Poultry, Equine, Ruminants, Pets, And Aquaculture), Animal Type, End-User, Form, and Region - Global Forecast to 2029
The global animal disinfectants market is estimated to be valued at USD 3.9 billion in 2024 and is projected to reach USD 5.7 billion by 2029, growing at a CAGR of 7.9% during the forecast period. The sharp rise in demand is primarily driven by growing awareness of biosecurity practices, especially in livestock and poultry farming. With increasing concerns over the spread of infectious animal diseases and zoonotic threats, the importance of effective disinfection protocols has surged—pushing the market forward.
Why Animal Disinfectants Are in High Demand?
Biosecurity is no longer optional—it's essential. With growing awareness of diseases such as avian influenza, swine fever, and foot-and-mouth disease, farmers and animal healthcare providers are investing in proper disinfection protocols. Disinfectants help eliminate pathogens from animal housing, equipment, and surroundings, reducing the risk of outbreaks.
Animal Disinfectants Market Growth Drivers
Rising Biosecurity Awareness: Frequent outbreaks of diseases such as African Swine Fever (ASF), Avian Influenza, and Foot-and-Mouth Disease have highlighted the importance of disinfecting livestock environments. Governments and industry bodies are enforcing stricter biosecurity norms, compelling farmers to adopt advanced disinfectants.
Intensification of Livestock Farming: As animal agriculture becomes more intensive, hygiene management becomes a top priority to avoid mass outbreaks that can severely affect productivity and economic returns. Disinfectants are vital for maintaining clean housing, equipment, and animal-contact surfaces.
Surge in Zoonotic Disease Risks: With increasing human-animal interactions, especially in developing countries, the risk of zoonotic disease transmission has escalated. Disinfectants play a preventive role in minimizing such risks on farms, in slaughterhouses, and during transportation.
Expansion of Poultry and Dairy Industries: The rapid growth of the poultry and dairy sectors is further supporting market expansion. These sectors are particularly vulnerable to disease outbreaks and thus rely heavily on routine cleaning and disinfection protocols.
Technological Advancements and New Formulations: The introduction of eco-friendly, non-toxic, and fast-acting disinfectants has enhanced product appeal. Innovations such as misting systems and automated sprayers have also improved the efficiency and ease of application.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=38718363
Poultry Segment to Witness Significant Growth
Among the various applications, the poultry segment is anticipated to record the fastest growth during the forecast period. Maintaining a disease-free environment is critical in poultry farming, where hygiene directly impacts animal health and product quality.
According to a 2021 OECD study, global meat protein consumption is expected to rise by 14% by 2030, with poultry meat comprising nearly 40% of total protein intake. This surge in demand is driving expansion in poultry farming, thereby increasing the need for reliable disinfectants to maintain hygienic conditions.
Commonly used disinfectants in poultry facilities include phenolic compounds, iodine, chlorine-based agents, quaternary ammonium compounds, and oxidizing agents. These are typically applied as fumigants, foam sprays, or liquid concentrates, following thorough equipment cleaning to eliminate residual pathogens. With avian influenza and other viral outbreaks becoming more prevalent, terminal disinfection has become a vital practice. For instance, Neogen Corporation (US), through its Quat-Chem division, offers virucidal disinfectants tailored to combat poultry diseases. In the EU, Germany stands out as the leading exporter of poultry products, contributing 24% of total regional exports—further highlighting the need for robust disinfection in high-output markets.
Powdered Disinfectants Gaining Popularity
Powdered animal disinfectants are projected to command a significant market share through 2029. Their popularity stems from advantages such as ease of application, safer handling, better shelf stability, and lower risk of spillage compared to liquid forms. Powders are especially effective in controlling biofilms, disinfecting hard-to-reach surfaces, and preventing cross-contamination.
An example of innovation in this space is Neogen's launch of Viroxide Super in March 2023—a peroxygen-based powdered disinfectant with approved virucidal claims in both the U.S. and Canada. This product is effective against a wide range of viruses, including avian influenza, PRRS, bovine viral diarrhea virus, and African swine fever. The combination of convenience and broad-spectrum efficacy makes powdered disinfectants a preferred choice in many farm settings.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=38718363
Asia Pacific Leads the Global Market
The Asia Pacific region holds the largest share of the animal disinfectants market, fueled by the growing need to manage disease outbreaks—particularly African Swine Fever (ASF). The region has experienced a wave of ASF cases, with recent outbreaks reported in countries such as India, Malaysia, and Singapore. In India alone, over 10,300 pigs were culled in Mizoram between February and July 2024, and an additional 310 in Kerala in early July.
These outbreaks underscore the urgent need for disease control and prevention, accelerating the adoption of animal disinfectants across the region. Governments and producers are increasingly investing in biosecurity solutions to curb the spread of ASF and other animal diseases, placing disinfectants at the center of disease management strategies. As a result, the Asia Pacific market is expected to continue driving global growth.
Leading Animal Disinfectants Companies:
Key market players in this include Neogen Corporation (US), GEA Group Aktiengesellschaftv (Germany), Lanxess (Germany), Zoetis (US), Solvay (Belgium), Stockmeier Group (Germany), Kersia Group (France), Ecolab (US), Albert Kerbl GmbH (Germany), PCC Group (Germany), DeLaval Inc. (Sweden), Diversey Holdings Ltd. (US), Virbac (France), Kemin Industries Inc. (US), and Fink Tec GmbH (Germany).
Key Questions Addressed by the Animal Disinfectants Market Report:
What is the animal disinfectants market?
What is the current size and projected growth of the animal disinfectants market?
What are the main drivers of growth in this market?
Which types of disinfectants are most commonly used in animal care?
What are the main application areas for animal disinfectants?
Which regions are leading in market adoption?
What challenges does the animal disinfectants market face?
What trends are shaping the future of the animal disinfectants market?
Why is the use of animal disinfectants important?
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
29 minutes ago
- CTV News
Amazon tumbles after cloud computing growth disappoints investors
shares fell seven per cent on Friday as the tech giant's results fanned investor fears its cloud unit was falling behind Microsoft and Alphabet in the artificial intelligence race. shares fell seven per cent on Friday as the tech giant's results fanned investor fears its cloud unit was falling behind Microsoft and Alphabet in the artificial intelligence race. Amazon Web Services, long the cloud-computing market leader, edged past Wall Street estimates for June-quarter revenue on Thursday with a 17.5 per cent increase, but it widely lagged the 39 per cent growth seen at Microsoft Azure and Google Cloud's 32 per cent gain. That disappointing growth came even as Amazon shelled out US$31.4 billion in capital expenditure, more than rivals, and suggested it would spend a more-than-estimated $118 billion for the year. Google and Microsoft also pledged higher spending, but were rewarded from investors on signs AI was already becoming a major growth driver across their businesses, justifying the bill. The companies have been spending billions of dollars on datacenters and cutting-edge chips that they say are necessary to overcome supply constraints hampering their efforts to capitalize on soaring demand for AI services. 'The spotlight was firmly on AWS and it didn't quite shine as brightly as expected,' said Matt Britzman, senior equity analyst at Hargreaves Lansdown. 'While Microsoft and Alphabet have already shown strong momentum in cloud growth, AWS wasn't the knockout many wanted to see.' Growing expenses have also started to take a bite out of AWS's margins, the business that has long been Amazon's profit engine, accounting for about 60 per cent of its operating income. AWS margins contracted to 32.9 per cent during the quarter, their lowest level since the final quarter of 2023, and Amazon also issued a current-quarter total operating income forecast that was lower than market estimates. CEO Andy Jassy told analysts on a post-earnings call that it was still 'very early days' in the AI race and that Amazon's massive cloud business, much larger than rivals, was primed to perform well once the AI capacity constraints start to ease. The stock, now down 1.5 per cent for the year, was at $216.2 in late morning trading. The drop was set to erase around $170 billion from Amazon's market value, if the losses hold. The company still trades at a relatively high premium, with a 12-month forward price-to-earnings ratio of 33.87, compared with Microsoft's 34.19 and Alphabet's 18.64, according to data compiled by LSEG. Retail resilience At least 30 analysts raised their price targets on the stock, while three lowered, giving it a median view of $260. Some of that analyst confidence comes from the strong performance of Amazon's retail business, which has remained resilient in the face of Trump administration tariffs that have hobbled many retailers and their supply chains. Amazon has yet to see a drop in demand or a notable rise in prices in the first half of the year, Jassy said, as its online store sales jumped a better-than-expected 11 per cent in the second quarter. Manufacturers and suppliers have shouldered most of the tariff impact so far, analysts said, but noted that much of the inventory Amazon sold in the quarter arrived in the preceding three-month period. 'If Amazon's retail business was a standalone entity, it would be trading dramatically higher following the near-perfect results,' said Michael Morton, analyst at MoffettNathanson. 'Unfortunately, as we all know, the success of the retail business is not what's going to matter in the near term for Amazon's stock price.' (Reporting by Aditya Soni and Kanchana Chakravarty in Bengaluru and Amanda Cooper in London; Editing by Alun John and Shilpi Majumdar)
Globe and Mail
29 minutes ago
- Globe and Mail
Coinbase Q2 Earnings and Revenues Miss Estimates, Volumes Rise Y/Y
Coinbase Global, Inc. COIN reported second-quarter 2025 net operating earnings per share of 12 cents, which missed the Zacks Consensus Estimate by 89.9%. The bottom line decreased 88.8% year over year. COIN witnessed lower crypto volatility and lower transaction revenue in the quarter while operating expenses increased. Operational Update Total trading volume increased 4.9% year over year to 237 million in the reported quarter. The Zacks Consensus Estimate was pegged at 235 million. Total revenues of $1.5 billion missed the Zacks Consensus Estimate by 0.5%. The top line, however, increased 3.2% year over year on higher transaction revenues, subscription and services revenues and other revenues. Total transaction revenues decreased 2.1% year over year to $764.3 million in the quarter. The decline was due to lower consumer transaction revenues as well as institutional transaction revenues. The Zacks Consensus Estimate was pegged at $795 million. Total subscription and services revenues increased 9.5% year over year to $655.8 million in the reported quarter. The growth was driven by higher stablecoin revenues. The Zacks Consensus Estimate was pegged at $692 million. Total operating expenses increased 37.5% to $1.5 billion in the quarter due to higher transaction expense, technology and development, sales and marketing and general and administrative expenses as well as other operating expense. Adjusted EBITDA was $512 million in the reported quarter, which fell 3.2% from the year-ago quarter. Financial Update Coinbase exited the second quarter with cash and cash equivalents of $7.5 billion as of June 30, 2025, down 11.8% from 2024-end. As of June 30, 2025, long-term debt increased 62.6% from 2024-end to $2.9 billion. Shareholders' equity was $12.1 billion at second-quarter 2025-end, up 17.7% from 2024-end. Net cash provided by operating activities was $145.7 million in first-half 2025, a drop of 83.7% year over year. Q3 2025 Outlook Coinbase expects subscription and services revenues to be in the range of $665-$745 million, driven primarily by higher average crypto prices and stablecoin revenues. Transaction expenses are expected to be in the mid-teens as a percent of net revenues. Coinbase expects technology and development and general and administrative expenses to be in the range of $800-$850 million, driven by headcount growth to support international expansion, new product initiatives and strengthening of customer support & security functions. Coinbase expects sales and marketing expenses to increase quarter over quarter to $190-$290 million, driven by potential variability in performance marketing and customer USDC balances in Coinbase products, which drive USDC reward. Zacks Rank COIN currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Peer Releases American Express Company AXP reported second-quarter 2025 earnings per share (EPS) of $4.08, which beat the Zacks Consensus Estimate by 5.7%. The bottom line climbed 17% year over year. Total revenues net of interest expense amounted to $17.9 billion, which outpaced the Zacks Consensus Estimate by 1%. The top line improved 9% year over year in the quarter under review. Network volumes of $472 billion rose 7% year over year in the second quarter, driven by higher U.S. consumer spending. Total interest income of $6.3 billion increased 8% year over year and beat the consensus mark by 0.4%. American Express still anticipates revenues to increase between 8% and 10% in 2025 from the 2024 level of $65.9 billion. Management expects EPS in the range of $15-$15.50, the midpoint of which indicates an improvement of 8.9% from the 2024 level of $14.01. Bread Financial Holdings ' BFH operating income of $3.14 per share for the second quarter of 2025 beat the Zacks Consensus Estimate by 69.7%. The bottom line improved 18% year over year. Revenues decreased 1.1% year over year to $929 million. The top line also missed the consensus estimate by 0.9%. Credit sales of $6.8 billion increased 4%, driven by new partner growth and increased general-purpose spending. Our estimate was $6.6 billion. Average loans of $17.7 billion decreased 1%. Management estimates average receivables to be flat to slightly down from 2024. It expects average credit card and other loans to be flat to slightly down from the 2024 level. Total revenues are estimated to be flat year over year. The net loss rate is guided in the range of 7.8-7.9%. Virtu Financial 's VIRT second-quarter operating income of $1.53 per share for the second quarter of 2025 beat the Zacks Consensus Estimate by 0.8%. The bottom line improved 84.3% year over year. Revenues increased 47.5% year over year to $929 million. The top line also beat the consensus estimate by 9.4%. Adjusted EBITDA increased 69.8% to $369.4 million. Adjusted EBITDA margin of 65.1% expanded 860 bps year over year. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report American Express Company (AXP): Free Stock Analysis Report Virtu Financial, Inc. (VIRT): Free Stock Analysis Report Coinbase Global, Inc. (COIN): Free Stock Analysis Report Bread Financial Holdings, Inc. (BFH): Free Stock Analysis Report
Globe and Mail
29 minutes ago
- Globe and Mail
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and AbbVie (ABBV)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY – Research Report) and AbbVie (ABBV – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Eli Lilly & Co (LLY) TD Cowen analyst Steve Scala maintained a Buy rating on Eli Lilly & Co today and set a price target of $960.00. The company's shares closed last Thursday at $763.28. According to Scala is a 4-star analyst with an average return of 6.7% and a 60.4% success rate. Scala covers the Healthcare sector, focusing on stocks such as Elanco Animal Health, GlaxoSmithKline, and Merck & Company. ;'> The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $1028.80 average price target, which is a 37.7% upside from current levels. In a report issued on July 17, TR | OpenAI – 4o also upgraded the stock to Buy with a $885.00 price target. AbbVie (ABBV) In a report released today, Matt Phipps from William Blair maintained a Buy rating on AbbVie. The company's shares closed last Thursday at $194.50. According to Phipps has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.6% and a 41.1% success rate. Phipps covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Janux Therapeutics Inc, and Vertex Pharmaceuticals. ;'> Currently, the analyst consensus on AbbVie is a Moderate Buy with an average price target of $212.46, which is a 7.8% upside from current levels. In a report issued on July 16, TR | OpenAI – 4o also upgraded the stock to Buy with a $206.00 price target.
